Juana Dornbusch1, Martina Walter2, Andrea Gottschalk3, Alice Obaje2, Kerstin Junker4, Carsten-Henning Ohlmann4, Matthias Meinhardt5, Aristeidis Zacharis1, Stefan Zastrow1, Olaf Schoffer6, Marc-Oliver Grimm2, Stefanie J Klug6, Manfred P Wirth1, Susanne Fuessel7. 1. Department of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 2. Department of Urology, University Hospital of Jena, Lessingstr. 1, 07743, Jena, Germany. 3. Institute for Medical Informatics and Biometry, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 4. Department of Urology, Saarland University Medical Center, Kirrberger Str. 1, 66424, Homburg, Germany. 5. Institute of Pathology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 6. Cancer Epidemiology, University Cancer Center Dresden, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. 7. Department of Urology, Technische Universität Dresden, Fetscherstr. 74, 01307, Dresden, Germany. susanne.fuessel@uniklinikum-dresden.de.
Abstract
PURPOSE: Single nucleotide polymorphisms (SNPs) in angiogenesis-associated genes might play an important role in activity of the tyrosine kinase inhibitor sunitinib and could affect survival of cancer patients treated with this drug. The aim of this retrospective study was to elucidate the role of 10 known SNPs in VEGFA, VEGFR1, VEGFR2 and VEGFR3 as potential prognostic and predictive markers in an independent cohort of patients with metastatic renal cell carcinoma (mRCC). METHODS: DNA from 121 mRCC patients treated with sunitinib was used to analyze SNPs by TaqMan genotyping assays. Disease control rate was evaluated according to RECIST. Adverse effects of sunitinib were registered from medical records. The results of Cox and logistic regression were verified by correction for multiple testing. RESULTS: Kaplan-Meier analysis revealed a reduced progression-free survival in patients with the wild-type (WT) allele of the VEGFA SNP rs699947 compared to variant alleles. Patients with the AA/AC-alleles of the VEGFR1 SNP rs9582036 had an improved median overall survival compared to those with the CC-WT allele what could be confirmed by multivariable Cox proportional hazard regression analyses. No statistically significant associations between the analyzed SNPs and higher risk for adverse effects were observed. CONCLUSIONS: The results of this study suggest that most of the selected SNPs in angiogenesis-related genes are not associated with survival of mRCC patients after sunitinib therapy or with adverse effects. Only the VEGFR1 SNP rs9582036 showed a statistically significant association with overall survival. The potential of SNPs as prognostic and predictive markers for sunitinib-treated mRCC patients should be finally assessed by prospective studies.
PURPOSE: Single nucleotide polymorphisms (SNPs) in angiogenesis-associated genes might play an important role in activity of the tyrosine kinase inhibitor sunitinib and could affect survival of cancerpatients treated with this drug. The aim of this retrospective study was to elucidate the role of 10 known SNPs in VEGFA, VEGFR1, VEGFR2 and VEGFR3 as potential prognostic and predictive markers in an independent cohort of patients with metastatic renal cell carcinoma (mRCC). METHODS: DNA from 121 mRCC patients treated with sunitinib was used to analyze SNPs by TaqMan genotyping assays. Disease control rate was evaluated according to RECIST. Adverse effects of sunitinib were registered from medical records. The results of Cox and logistic regression were verified by correction for multiple testing. RESULTS: Kaplan-Meier analysis revealed a reduced progression-free survival in patients with the wild-type (WT) allele of the VEGFA SNP rs699947 compared to variant alleles. Patients with the AA/AC-alleles of the VEGFR1 SNP rs9582036 had an improved median overall survival compared to those with the CC-WT allele what could be confirmed by multivariable Cox proportional hazard regression analyses. No statistically significant associations between the analyzed SNPs and higher risk for adverse effects were observed. CONCLUSIONS: The results of this study suggest that most of the selected SNPs in angiogenesis-related genes are not associated with survival of mRCC patients after sunitinib therapy or with adverse effects. Only the VEGFR1 SNP rs9582036 showed a statistically significant association with overall survival. The potential of SNPs as prognostic and predictive markers for sunitinib-treated mRCC patients should be finally assessed by prospective studies.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Meta H M Diekstra; Jesse J Swen; Epie Boven; Daniel Castellano; Hans Gelderblom; Ron H J Mathijssen; Cristina Rodríguez-Antona; Jesus García-Donas; Brian I Rini; Henk-Jan Guchelaar Journal: Eur Urol Date: 2015-04-27 Impact factor: 20.096
Authors: Hye Ryun Kim; Hyung Soon Park; Woo Sun Kwon; Ji Hyun Lee; Yusuke Tanigawara; Sun Min Lim; Hyo Song Kim; Sang Jun Shin; Jung Bae Ahn; Sun Young Rha Journal: Cancer Chemother Pharmacol Date: 2013-09-08 Impact factor: 3.333
Authors: Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne Journal: J Pathol Date: 2010-06 Impact factor: 7.996
Authors: Pablo Sáenz-López; Fernando Vazquez; Jose Manuel Cozar; Rafael Carretero; Federico Garrido; Francisco Ruiz-Cabello Journal: Hum Immunol Date: 2012-10-13 Impact factor: 2.850
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Robert J Motzer; Jennifer Bacik; Lawrence H Schwartz; Victor Reuter; Paul Russo; Stephanie Marion; Madhu Mazumdar Journal: J Clin Oncol Date: 2004-02-01 Impact factor: 44.544
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: K Eechoute; A A M van der Veldt; S Oosting; M H W Kappers; J A M Wessels; H Gelderblom; H-J Guchelaar; A K L Reyners; C M L van Herpen; J B Haanen; R H J Mathijssen; E Boven Journal: Clin Pharmacol Ther Date: 2012-09-05 Impact factor: 6.875
Authors: Robert J Motzer; Thomas E Hutson; Gary R Hudes; Robert A Figlin; Jean-Francois Martini; Patricia A English; Xin Huang; Olga Valota; J Andrew Williams Journal: Cancer Chemother Pharmacol Date: 2014-08-07 Impact factor: 3.333
Authors: Daniel J George; Jean-Francois Martini; Michael Staehler; Robert J Motzer; Ahmed Magheli; Frede Donskov; Bernard Escudier; Sherry Li; Michelle Casey; Olga Valota; Brigitte Laguerre; Allan J Pantuck; Hardev S Pandha; Anup Patel; Maria Lechuga; Alain Ravaud Journal: Clin Cancer Res Date: 2018-11-06 Impact factor: 12.531
Authors: Xiaoyan Liu; Jesse J Swen; Epie Boven; Daniel Castellano; Hans Gelderblom; Ron H J Mathijssen; Cristina Rodríguez-Antona; Jesus García-Donas; Brian I Rini; Henk-Jan Guchelaar Journal: Oncotarget Date: 2017-01-03
Authors: Carmen Garrigós; Marta Espinosa; Ana Salinas; Ignacio Osman; Rafael Medina; Miguel Taron; Sonia Molina-Pinelo; Ignacio Duran Journal: Oncotarget Date: 2017-11-20
Authors: David Blánquez-Martínez; Xando Díaz-Villamarín; Sonia García-Rodríguez; Alba Antúnez-Rodríguez; Ana Pozo-Agundo; Luis Javier Martínez-González; José Ignacio Muñoz-Ávila; Cristina Lucía Dávila-Fajardo Journal: Pharmaceutics Date: 2022-07-26 Impact factor: 6.525